JAMIE LUMMUS: Open Payments
NPI 1417401415 · SPOKANE, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,894 in 62 payments from 29 companies in 2025. Trend: 2023 $224 · 2024 $1,329 · 2025 $1,894
Food & beverage: $1,894
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 2 | $289 |
| PFIZER INC. | 8 | $170 |
| ABBVIE INC. | 7 | $167 |
| AstraZeneca Pharmaceuticals LP | 5 | $157 |
| Janssen Biotech, Inc. | 3 | $137 |
| Regeneron Healthcare Solutions, Inc. | 1 | $135 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $98 |
| Genentech USA, Inc. | 4 | $93 |
| Novartis Pharmaceuticals Corporation | 4 | $79 |
| Secura Bio, Inc. | 2 | $57 |
Products named: SARCLISA, LYNOZYFIC, IMFINZI, RYBREVANT, IBRANCE, EPKINLY, ICLUSIG, IMBRUVICA.
Industry payments across WA — which companies pay providers there.
